Arkuda Therapeutics
PrivateLast Round
Series B
Feb 10, 2022
Total Funding Raised
$108M
Company Overview
Arkuda Therapeutics is a biotechnology company that develops neurodegenerative medicines by leveraging insights into progranulin and lysosomal biology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arkuda Therapeutics Comparables
Compare Arkuda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vesper Bio ApS | 87% | |
| Vanqua Bio | 80% | |
| Muna Therapeutics | 80% |
Arkuda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2022 | ||||
| Series A | Nov 7, 2019 |
Arkuda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Series B |
| Cormorant Asset Management | Series B |
| BioInnovation Capital | Series A, Series B |
| Pivotal bioVenture Partners | Series B |
| Tekla Capital Management | Series A, Series B |
| Nan Fung Group | Series B |
| Citadel | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 10, 2022
$64M round led by Cormorant Asset Management, Pivotal bioVenture Partners China, and Nan Fung Group.
- Nov 7, 2019
$44M round led by Pfizer Ventures and Atlas Venture.
Arkuda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Arkuda Therapeutics's valuation, stock price, and market status.
Is Arkuda Therapeutics a public or private company?
Arkuda Therapeutics is a private company.
What is the current stock price of Arkuda Therapeutics?
Arkuda Therapeutics is a private company, so its shares have no public market price. Caplight tracks Arkuda Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Arkuda Therapeutics worth (valuation)?
Valuation information for Arkuda Therapeutics is not publicly available.
Can I buy Arkuda Therapeutics stock?
Arkuda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Arkuda Therapeutics's last funding round?
Arkuda Therapeutics's most recent funding round was Series B on February 10, 2022.
Who are the main investors in Arkuda Therapeutics?
Key investors in Arkuda Therapeutics include Cormorant Asset Management, Pivotal bioVenture Partners, Nan Fung Group, Pfizer Ventures, Pivotal bioVenture Partners.
Will Arkuda Therapeutics IPO soon?
No public IPO plans have been announced for Arkuda Therapeutics.
How can I track Arkuda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Arkuda Therapeutics's shares on secondary markets.